Contraindicated (one)bortezomib will improve the amount or influence of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or moderate CYP2C19 inhibitors might improve mavacamten systemic publicity, leading to heart failure because of systolic dysfunction.Acute advancement or exacerbation of congestive heart failur